Jiaxian Ong

Jiaxian Ong

Auto-generated profile, based on publicly available information

Jiaxian Ong


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2025 in Advanced Pharmaceutical Bulletin
Verified
Journal Article
Closed access
JOJiaxian Ong
Jiaxian Ong
SSSharanya Sritharan
Sharanya Sritharan
AAAmar Harris Bin Arifin
Amar Harris Bin Arifin
BGBaskaran Gunasekaran
Baskaran Gunasekaran
RKRhun Yian Koh
Rhun Yian Koh
SSShamala Salvamani
Shamala Salvamani
Colorectal cancer (CRC) is one of the most prevalent cancers in the world, which affects developed countries the most. Many pathways and mechanisms were attributed as the cause of CRC, and one of the targets of interest is the long non-coding ribonucleic acid (lncRNA), growth arrest specific 5 (GAS5). GAS5 have been observed to play an important role in many other cancers, and CRC is not an exception. This paper aims to understand the role and mechanisms played by GAS5 in relation to CRC progression. It is found that GAS5 have a complex role, and a major one being its competitive endogenous nature that could downregulate multiple microRNAs such as miR-485-5p, miR-137, miR-26b, miR-21, miR34a, miR-182-5p, miR-128-30, and miR-221, which have implications in tumour growth and suppression. It is also observed to be able to interact with proteins directly, such as the Yes-Associated Protein (YAP). Both clinical and laboratory evidence support the fact that in the context of CRC, GAS5 overexpression is a protective factor, while its underexpression is related to worse prognosis and survival rate. This has opened up its potential as a prognostic biomarker, as well as a therapeutic target to treat multiple cancers, including CRC. However, more research is still required to answer the knowledge gap. In conclusion, GAS5 plays multiple roles and is an important player in cancer regulation, including CRC, and it holds good potential to be a biomarker and a therapeutic target.